Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study - 26/09/12
, Bart Neyns, MD b, Gerald Linette, MD c, Sylvie Negrier, ProfMD d, Jose Lutzky, MD e, Luc Thomas, ProfMD f, William Waterfield, MD g, Dirk Schadendorf, ProfMD h, Michael Smylie, ProfMD i, Troy Guthrie, MD j, Jean-Jacques Grob, ProfMD k, Jason Chesney, MD l, Kevin Chin, MD m, Kun Chen, PhD m, Axel Hoos, MD m, Steven J O’Day, MD n, Celeste Lebbé, ProfMD oSummary |
Background |
Ipilimumab is a human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen 4 and has shown promising activity in advanced melanoma. We aimed to ascertain the antitumour efficacy of ipilimumab in patients with advanced melanoma.
Methods |
We undertook a randomised, double-blind, phase 2 trial in 66 centres from 12 countries. 217 patients with previously treated stage III (unresectable) or stage IV melanoma were randomly assigned a fixed dose of ipilimumab of either 10 mg/kg (n=73), 3 mg/kg (n=72), or 0·3 mg/kg (n=72) every 3 weeks for four cycles (induction) followed by maintenance therapy every 3 months. Randomisation was done with a permuted block procedure, stratified on the basis of type of previous treatment. The primary endpoint was best overall response rate (the proportion of patients with a complete or partial response, according to modified WHO criteria). Efficacy analyses were done by intention to treat, whereas safety analyses included patients who received at least one dose of ipilimumab. This study is registered with ClinicalTrials.gov, number NCT00289640.
Findings |
The best overall response rate was 11·1% (95% CI 4·9–20·7) for 10 mg/kg, 4·2% (0·9–11·7) for 3 mg/kg, and 0% (0·0–4·9) for 0·3 mg/kg (p=0·0015; trend test). Immune-related adverse events of any grade arose in 50 of 71, 46 of 71, and 19 of 72 patients at doses of 10 mg/kg, 3 mg/kg, and 0·3 mg/kg, respectively; the most common grade 3–4 adverse events were gastrointestinal immune-related events (11 in the 10 mg/kg group, two in the 3 mg/kg group, none in the 0·3 mg/kg group) and diarrhoea (ten in the 10 mg/kg group, one in the 3 mg/kg group, none in the 0·3 mg/kg group).
Interpretation |
Ipilimumab elicited a dose-dependent effect on efficacy and safety measures in pretreated patients with advanced melanoma, lending support to further studies at a dose of 10 mg/kg.
Funding |
Bristol-Myers Squibb.
Le texte complet de cet article est disponible en PDF.Plan
Vol 11 - N° 2
P. 155-164 - février 2010 Retour au numéro
Article précédent
- Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial
- Jacques Irani, Laurent Salomon, Rostand Oba, Philippe Bouchard, Nicolas Mottet
- Cancer survival in Africa, Asia, and Central America: a population-based study
- Rengaswamy Sankaranarayanan, Rajaraman Swaminathan, Hermann Brenner, Kexin Chen, Kee Seng Chia, Jian Guo Chen, Stephen CK Law, Yoon-Ok Ahn, Yong Bing Xiang, Balakrishna B Yeole, Hai Rim Shin, Viswanathan Shanta, Ze Hong Woo, Nimit Martin, Yupa Sumitsawan, Hutcha Sriplung, Adolfo Ortiz Barboza, Sultan Eser, Bhagwan M Nene, Krittika Suwanrungruang, Padmavathiamma Jayalekshmi, Rajesh Dikshit, Henry Wabinga, Divina B Esteban, Adriano Laudico, Yasmin Bhurgri, Ebrima Bah, Nasser Al-Hamdan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?